secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001493152-26-005199
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

Telomir Pharmaceuticals Reports Preclinical Data on Telomir-Zn Modulating Metal Balance
--------------------------------------------------------------------------------

- Telomir-Zn induced rapid intracellular zinc increase and labile ferrous iron reduction within 30 minutes in preclinical studies.
- Coordinated metal redistribution observed without loss of cell confluence or viability, supporting a non-cytotoxic mechanism.
- Findings implicate epigenetic modulation, oxidative stress reduction, and mitochondrial stabilization in cancer and aging models.
- Company advancing IND-enabling activities with planned IND submission in Q1 2026.
- Manuscript submissions initiated for peer-reviewed journals based on completed studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226005199/0001493152-26-005199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226005199/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-005199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer